Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Vaccine ; 20(5-6): 797-804, 2001 Dec 12.
Artículo en Inglés | MEDLINE | ID: mdl-11738743

RESUMEN

The recombinant Mycobacterium bovis BCG (rBCG) vector-based vaccine secreting the V3 principal neutralizing epitope of human immunodeficiency virus type 1 (HIV-1) Japanese strain was reported to induce both humoral and cellular immune responses effectively [Proc. Natl. Acad. Sci. USA. 92 (1995) 10693]. The antigen-secreting rBCG system was applied to the V3 epitope of clade E HIV-1 in this study. The V3 sequence of 19 amino acids (aa) and 15aa fused with mycobacterial alpha-antigen was not secreted while 12aa and 11aa sequences were successfully secreted from BCG cells. Serum IgG from guinea pig which was immunized with 12aa epitope-secreting recombinant BCG neutralized the WHO reference strain as well as primary field isolates of clade E virus. The serum IgG could also neutralize Thai B (clade B') strains which possessed a conserved GPGQ motif in their V3 sequences. These data suggest that the rBCG construct secreting the 12aa epitope is implicated in the development of a prophylactic vaccine in Thailand in which both clade E and B' viruses are prevalent.


Asunto(s)
Vacunas contra el SIDA/farmacología , Vacuna BCG/farmacología , Anticuerpos Anti-VIH/biosíntesis , VIH-1/clasificación , VIH-1/inmunología , Vacunas contra el SIDA/genética , Vacunas contra el SIDA/inmunología , Secuencia de Aminoácidos , Animales , Vacuna BCG/genética , Vacuna BCG/inmunología , Epítopos/genética , Vectores Genéticos , Cobayas , Proteína gp120 de Envoltorio del VIH/genética , Proteína gp120 de Envoltorio del VIH/inmunología , Infecciones por VIH/virología , VIH-1/genética , Humanos , Datos de Secuencia Molecular , Mycobacterium bovis/genética , Pruebas de Neutralización , Fragmentos de Péptidos/genética , Fragmentos de Péptidos/inmunología , Tailandia , Vacunas Sintéticas/genética , Vacunas Sintéticas/inmunología , Vacunas Sintéticas/farmacología
2.
Jpn J Cancer Res ; 88(9): 787-91, 1997 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-9369924

RESUMEN

A high rate of human T-lymphotropic virus type II (HTLV-II) infection has been documented in intravenous drug abusers (IVDAs) in South Vietnam. We have investigated the molecular characteristics of the virus and have shown that one HTLV-II subtype is predominant in Ho Chi Minh City. This molecular subtype, HTLV-IIb, was identified in a number of South Vietnamese by nucleotide sequence analysis of the long terminal repeat (LTR) region. HTLV-IIa was not found. These findings suggest that HTLV-IIb is endemic in IVDAs in South Vietnam, although IVDAs in urban areas in North America are predominantly infected with HTLV-IIa.


Asunto(s)
Variación Genética , Infecciones por HTLV-II/virología , Virus Linfotrópico T Tipo 2 Humano/genética , Secuencias Repetitivas de Ácidos Nucleicos , Adulto , Secuencia de Bases , Anticuerpos Anti-HTLV-II/sangre , Infecciones por HTLV-II/transmisión , Virus Linfotrópico T Tipo 2 Humano/aislamiento & purificación , Humanos , Masculino , Datos de Secuencia Molecular , América del Norte , Filogenia , Alineación de Secuencia , Abuso de Sustancias por Vía Intravenosa , Población Urbana , Vietnam
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA